INT92504

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 19
Disease Relevance 8.98
Pain Relevance 6.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Ccl2) aging (Ccl2) extracellular region (Ccl2)
cytoskeleton organization (Ccl2) cytoplasm (Ccl2)
Anatomy Link Frequency
monocyte 4
neurons 2
blood 1
spinal 1
medial 1
Ccl2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 235 100.00 Very High Very High Very High
cytokine 54 100.00 Very High Very High Very High
dexamethasone 4 99.98 Very High Very High Very High
chemokine 29 99.80 Very High Very High Very High
Calcitonin gene-related peptide 10 99.24 Very High Very High Very High
antagonist 83 99.16 Very High Very High Very High
Kinase C 3 98.68 Very High Very High Very High
allodynia 10 97.44 Very High Very High Very High
Potency 12 97.04 Very High Very High Very High
Pain 21 97.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 280 100.00 Very High Very High Very High
Arthritis 47 99.84 Very High Very High Very High
Hyperglycemia 2 99.48 Very High Very High Very High
Infection 7 99.28 Very High Very High Very High
Necrosis 6 99.16 Very High Very High Very High
Cancer 9 98.98 Very High Very High Very High
Stress 35 98.32 Very High Very High Very High
Neuropathic Pain 134 97.44 Very High Very High Very High
Pain 27 97.00 Very High Very High Very High
Ganglion Cysts 6 96.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These pronociceptive effects of CCL2 are completely prevented by the selective CCR2 antagonist (INCB3344), indicating that CCL2-induced pain facilitation is elicited via direct spinal activation of CCR2 receptor.
Negative_regulation (prevented) of CCL2 in spinal associated with pain and antagonist
1) Confidence 0.43 Published 2008 Journal J. Neurochem. Section Abstract Doc Link 18419759 Disease Relevance 0.65 Pain Relevance 1.18
Pretreatment of DRG neurons for 30 min with the inhibitors of phospholipase C (PLC) and protein kinase C (PKC) but not mitogen-activated protein kinases (MAPKs) significantly reduced CCL2- or CXCL1-induced CGRP release and intracellular calcium elevation.
Negative_regulation (reduced) of CCL2 in neurons associated with dorsal root ganglion, kinase c and calcitonin gene-related peptide
2) Confidence 0.41 Published 2005 Journal J. Neurosci. Res. Section Abstract Doc Link 16047385 Disease Relevance 0.77 Pain Relevance 1.12
The concentrations of the cytokines interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha and the chemokines CCL5 and CCL2 were significantly decreased in arthritic rats treated with atorvastatin.
Negative_regulation (decreased) of CCL2 associated with chemokine, necrosis, cancer, arthritis and cytokine
3) Confidence 0.38 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15970284 Disease Relevance 0.77 Pain Relevance 0.44
Indeed, when using 1% halothane, polymorphonuclear leukocyte (PMN) recruitment was decreased by 55% (p < 0.001) and TNF-alpha, IL-6, and MIP-2 concentrations in BALF and lung homogenates were decreased by more than 60% (p < 0.001) whereas total protein and MCP-1 concentrations remained unchanged.
Negative_regulation (decreased) of MCP-1 in polymorphonuclear leukocyte associated with halothane
4) Confidence 0.36 Published 2000 Journal Am. J. Respir. Crit. Care Med. Section Abstract Doc Link 11112152 Disease Relevance 0.65 Pain Relevance 0.85
Results show that the effect of high glucose on lipid peroxidation, IL-6, IL-8, MCP-1, and TNF-alpha secretion was inhibited by curcumin in cultured monocytes.
Negative_regulation (inhibited) of MCP-1 in monocytes
5) Confidence 0.35 Published 2009 Journal Antioxid. Redox Signal. Section Abstract Doc Link 18976114 Disease Relevance 0.58 Pain Relevance 0.17
This study examined the hypothesis that curcumin supplementation decreases blood levels of IL-6, MCP-1, TNF-alpha, hyperglycemia, and oxidative stress by using a cell-culture model and a diabetic rat model.
Negative_regulation (decreases) of MCP-1 in blood associated with stress, hyperglycemia and diabetes mellitus
6) Confidence 0.35 Published 2009 Journal Antioxid. Redox Signal. Section Abstract Doc Link 18976114 Disease Relevance 0.45 Pain Relevance 0.06
However, MCP-1 inhibition persisted until 24 h. rmIL-1beta-induced MIP-2 and tumor necrosis factor-alpha mRNA expression were decreased by 36 and 24%, respectively, after halothane exposure.
Negative_regulation (inhibition) of MCP-1
7) Confidence 0.32 Published 2003 Journal Anesthesiology Section Body Doc Link 12502982 Disease Relevance 0 Pain Relevance 0
Intramuscular injection of a plasmid encoding a 7-terminal deleted dominant negative inhibitor of MCP-1 in rats simultaneously injected with MCT inhibited the progression of MCT-induced PAH, RV hypertrophy, medial hypertrophy of pulmonary arterioles, and mononuclear cell infiltration into the lungs [55].

2.2.3.

Negative_regulation (inhibitor) of MCP-1 in medial associated with hypertrophy and pulmonary hypertension
8) Confidence 0.32 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.72 Pain Relevance 0.05
In our study, the association between high levels of MCP-1 and abnormal glucose regulation may indicate that patients with an abnormal glucometabolic status do present with high levels of MCP-1 before the acute STEMI or it might be suggested that patients with abnormal glucose regulation respond with higher levels of MCP-1 in the acute phase, compared to those with normal glucose regulation.
Negative_regulation (present) of MCP-1
9) Confidence 0.32 Published 2010 Journal Cardiovasc Diabetol Section Body Doc Link PMC2940874 Disease Relevance 0.55 Pain Relevance 0.07
This finding is rather unexpected because a direct vasodilatory effect of MCP-1 has not, to our knowledge, been described yet.
Negative_regulation (effect) of MCP-1
10) Confidence 0.30 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2949609 Disease Relevance 0.25 Pain Relevance 0.03
Tacrolimus and dexamethasone decreased IL-6, iNOS and MCP-1.
Negative_regulation (decreased) of MCP-1 associated with dexamethasone
11) Confidence 0.26 Published 2002 Journal Acta Otolaryngol. Section Abstract Doc Link 12030571 Disease Relevance 0.45 Pain Relevance 0.32
In DRG neurons, incubation with AZ889 (5 min) produced a concentration-dependent inhibition of the rCCL2 (100 nM) evoked calcium response with an IC50 of 1.5 nM (Figure 3D-E).
Negative_regulation (inhibition) of rCCL2 in neurons
12) Confidence 0.26 Published 2010 Journal Mol Pain Section Body Doc Link PMC3009975 Disease Relevance 0.16 Pain Relevance 0.08
In the absence of extracellular calcium, the peak CCL2-evoked calcium rise was reduced, but this difference was not significant (p > 0.05, n = 9 cells, Figure 3F) suggesting that intracellular stores are the principal source of calcium mediating this response.
Negative_regulation (reduced) of CCL2-evoked
13) Confidence 0.19 Published 2010 Journal Mol Pain Section Body Doc Link PMC3009975 Disease Relevance 0.15 Pain Relevance 0.07
A potent antagonist, AZ889, was identified for competitively inhibiting mCCL2-evoked calcium response with an observed median inhibition concentration (IC50) potency value of 1.3 ± 0.2 nM (n = 5; Figure 1).
Negative_regulation (inhibiting) of mCCL2-evoked associated with antagonist and potency
14) Confidence 0.19 Published 2010 Journal Mol Pain Section Body Doc Link PMC3009975 Disease Relevance 0.11 Pain Relevance 0.24
Most treatments decreased MCP-1 and four decreased IL-6 and iNOS.
Negative_regulation (decreased) of MCP-1
15) Confidence 0.17 Published 2002 Journal Acta Otolaryngol. Section Abstract Doc Link 12030571 Disease Relevance 0.46 Pain Relevance 0.32
This latter finding is discrepant with the study by de Visser and collaborators [15] who showed significant decrease of MCP-1 and IL-6 mRNAs on day 10 of exposure.
Negative_regulation (decrease) of MCP-1
16) Confidence 0.14 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2563688 Disease Relevance 0.53 Pain Relevance 0.28
The ability of RU to decrease MCP-1 levels in vivo and in vitro may add to its beneficial effects because this cytokine is a potent stimulator of monocyte recruitment into the site of inflammation [38].
Negative_regulation (decrease) of MCP-1 in monocyte associated with inflammation and cytokine
17) Confidence 0.10 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2374451 Disease Relevance 0.80 Pain Relevance 0.45
Equally, anti-inflammatory effects of PC as well as LPC could be proofed by the downregulation of pro-inflammatory cytokines such as IL-8, monocyte chemotactic protein-1 (MCP-1) and interferon ?
Negative_regulation (downregulation) of monocyte chemotactic protein-1 in monocyte associated with inflammation and cytokine
18) Confidence 0.06 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2996791 Disease Relevance 0.46 Pain Relevance 0.28
Equally, anti-inflammatory effects of PC as well as LPC could be proofed by the downregulation of pro-inflammatory cytokines such as IL-8, monocyte chemotactic protein-1 (MCP-1) and interferon ?
Negative_regulation (downregulation) of MCP-1 in monocyte associated with inflammation and cytokine
19) Confidence 0.06 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2996791 Disease Relevance 0.46 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox